For the three months ended September 30, 2025, the Company reported a net loss of $4.2 million, or $4.64 per share, compared to a net loss of $5.1 million, or $1,092 per share, for the same period in ...

DARE-HPV: Currently funded by an ARPA-H award and NIH grant; in development as a novel intravaginal therapy to treat persistent high-risk genital human papillomavirus (HPV) infections in women and ...